ArticleJTO clinical and research reports2025

Corrigendum to "Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC [JTO Clinical and Research Reports Vol. 4 No. 1: 100431].

Marina C Garassino et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.